JJJonathan Nicholas Johnson

Jonathan Nicholas Johnson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jonathan Nicholas Johnson has a total of 460 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • SMARTER Education for a Global Transplant Workforce

    by Rupesh Raina, Carlos Esquivel, Sydney Smith, Ruhaan Bajpai, Jonathan N. Johnson, Mignon McCulloch, Jun Oh, Lars Pape, C. Andrew Bonham, Sharon Bartosh, et al.

    IPTA created the SMARTER Initiative to address persistent gaps in pediatric transplant education worldwide. Through webinars, podcasts, case discussions, and interactive resources, SMARTER provides trainees and allied professionals with accessible, peer‐reviewed content across all major organ systems. The program is designed for global reach, with downloadable modules, mobile compatibility, and recorded sessions to accommodate different regions and time zones. Since its launch, SMARTER has shown strong engagement, with fellows reporting that the platform helps them prepare for board exams, improve clinical decision‐making, and connect learning directly to patient care. Survey feedback highlights high satisfaction and identifies opportunities for further growth, such as expanded case‐based modules, procedural videos, and simulation exercises. By reducing disparities in transplant training and supporting collaboration, SMARTER is positioned to strengthen existing curricula and promote a better‐prepared, more globally connected transplant workforce.


  • HeartWare™ HVAD support without anticoagulation

    by Mats Steffi Jennifer Masilamani, Emily Greengard, Jonathan Nicholas Johnson, Rebecca Ameduri

    Ventricular assist devices (VADs) are being increasingly used in pediatric patients as a bridge to heart transplant (HTx ) candidacy, significantly reducing waitlist mortality. We report a case of an 8-year-old girl with high-grade osteosarcoma who developed anthracycline-induced cardiomyopathy (AC), leading to acute systolic heart failure. Due to persistent dual-inotropic dependence, a HeartWare™ left ventricular assist device (HVAD) was placed. Complicating her course, she experienced a local recurrence of her malignancy, necessitating further chemotherapy. While on anticoagulation for her HVAD and due to thrombocytopenia, she developed refractory epistaxis which required discontinuation of anticoagulant and antiplatelet agents for over 110 days. After 21 months of remission, she was listed status 1A for HTx and successfully received a transplant after a 3-month wait. Our experience suggests that with careful clinical and laboratory monitoring, durable HVAD support can be maintained in certain critical situations, without the use of anticoagulant or antiplatelet agents. This case underscores the importance of a multidisciplinary team approach, along with enhanced patient and family education, to minimize complications and optimize outcomes. We also highlight the evolving antithrombotic strategies in VAD patients, with Antiplatelet Removal and Hemocompatibility Events with a HeartMate 3 (ARIES-HM3) trial supporting aspirin avoidance; however, applying these results to other VADs warrants considerable caution.


  • Open Access

    Pediatric Heart Failure: A Practical Guide for Primary Care Providers Supporting Families Across the Care Continuum

    by Shahnawaz Amdani, Kriti Puri, Julie Glickstein, Joseph A. Spinner, Jonathan N. Johnson, Ashraf S. Harahsheh, Majd Makhoul, Susan Denfield

    Background/Objectives: Pediatric heart failure (HF) is a complex clinical syndrome with diverse etiologies and presentations. Primary care providers (PCPs) are critical in early recognition, family education, and coordination of ongoing care in collaboration with pediatric cardiologists. This review provides a comprehensive guide for PCPs to understand the causes, symptoms, treatments, and longitudinal considerations for children with HF. Methods: We conducted a narrative review synthesizing published evidence and expert consensus guidelines, focusing on the clinical presentation, treatment options, and longitudinal care strategies in children with HF. Results: HF in children most commonly results from congenital heart disease and cardiomyopathy, but includes a wide range of etiologies. Presenting symptoms differ by age, with subtle signs often mistaken for common pediatric illnesses. Treatments range from disease-modifying medications to surgical and transplant therapies. Psychosocial support, mental health, and family-centered care are critical components of long-term management. Conclusions: PCPs are essential partners in the care of children with HF. A proactive, collaborative, and informed approach can improve quality of life, reduce hospitalizations, and support families navigating this challenging diagnosis.


  • Transplant Pharmacist Intervention During Pediatric Care Center Transfers: An Unaddressed Gap

    by Rachel Huntsman, Molly Fenske, Adley Lemke, Kerry Schueler, Michele DiCarlo, Karen Kolbet, Molly McCord, Ashley Rosier, Jonathan N. Johnson, Rebecca Ameduri, et al.

    Background: Risk for medication error increases during care transitions. Error susceptibility increases in pediatrics due to age and weight‐based dosing. Governing bodies acknowledge errors endanger patients, and transplant pharmacotherapy experts are mandated by the Center for Medicare and Medicaid Services (CMS). Pharmacist‐led medication histories reduce errors; however, pharmacists' roles in the transitions of care between transplant centers are unaddressed by CMS. We assessed the impact of transplant pharmacist involvement in medication histories for pediatrics transitioning between transplant centers. Methods: Pediatric patients pre‐ or post‐heart transplant transitioning to our center were proactively identified. Transplant pharmacists conducted medication histories by phone with caregivers and tracked discrepancies between existing medication lists and interview responses. Descriptive statistical analyses were completed. Results: Of 27 patients identified, seven caregivers were uncontactable, one declined participation, and 19 underwent transplant pharmacist medication history. Medication list errors were detected in 100% of patients ( n = 19), with a median [IQR] of 5 [3–11] issues per patient. Of 122 issues, 72 (59%) were inaccurate or missing data, 17.2% ( n = 21) listed stopped drugs, 9.8% ( n = 12) revealed incorrect administration routes, 7.4% ( n = 9) were duplicate medications, and 6.6% ( n = 8) of errors were medications needing to be added. Corrections included updating 84 inaccuracies (68.8%); removing/adding drugs (30 [24.6%] and 8 [6.6%], respectively); and team communication. Conclusions: Complex dosing strategies in pediatrics confer error vulnerability. Designing transition of care processes with transplant pharmacist involvement in medication histories can assist in ensuring medication list accuracy, thereby improving pediatric patient safety.


  • Successful Utilization of Organ Care System in Three Pediatric Heart Transplant Recipients

    by Liwei Yu, Jonathan N. Johnson, Richard C. Daly, Joseph A. Dearani, Elizabeth H. Stephens, Mauricio A. Villavicencio, Frank A. Reynolds, Rebecca K. Ameduri

    Introduction: Improving organ preservation is essential for expanding the donor pool and enhancing outcomes for pediatric transplant recipients. This report presents three pediatric patients who received donor hearts preserved using the Organ Care System (OCS). All donor hearts were prepared, placed, and monitored on OCS according to standard protocols. Heart function and myocardial edema were visually assessed during monitoring. Case Reports: Patient 1: A 17‐year‐old female patient with hypertrophic cardiomyopathy utilized OCS technology due to donor distance. She experienced an uncomplicated post‐transplant course and was discharged on post‐transplant day 10. Patient 2: A 14‐year‐old male patient with complex congenital heart disease, palliated with Fontan circulation, underwent orthotopic heart transplantation (OHT) with OCS support due to both the complexity of the procedure and donor heart distance. His post‐transplant course was complicated by a revision of the ascending aorta anastomosis and prolonged milrinone infusion for diastolic dysfunction. He was discharged on post‐transplant day 31. Patient 3: A 16‐year‐old male patient with hypoplastic left heart syndrome, also palliated with Fontan circulation, underwent OHT using OCS technology due to the complexity of the surgical procedure. His post‐transplant recovery was unremarkable, and he was discharged on post‐transplant day 15. Conclusions: All three pediatric patients demonstrated favorable short‐term outcomes using OCS technology. The OCS system facilitated shorter ischemic times despite the need for extended transport distances or complex surgical procedures. However, further studies with larger patient cohorts and longer follow‐up are needed to better understand the long‐term impact of OCS on pediatric heart transplantation outcomes.


  • Transcatheter Pulmonary Flow Restrictors as a Palliative Bridge to Heart Transplant

    by Mats Steffi Jennifer Masilamani, Jonathan N. Johnson, Rebecca K. Ameduri, Elizabeth H. Stephens, Allison K. Cabalka, Jason H. Anderson

    Background: In recent years, transcatheter implantation devices to restrict pulmonary arterial flow have emerged as a potential alternative to surgical pulmonary artery banding.Case Presentation: A term male was diagnosed with critical aortic stenosis (AS) and severely reduced left ventricle (LV) systolic function. He underwent aortic balloon valvuloplasty on day 2 of life, resulting in some antegrade flow, but LV ejection fraction only improved to 15%. He remained ductal dependent for systemic perfusion. Pulmonary over‐circulation ensued with systemic steal evident in his second week of life. On day 14, he underwent a transcatheter stage 1 procedure including the placement of bilateral pulmonary flow restrictor (PFR) devices and ductal stenting. Post‐procedure, he improved clinically, weaned off respiratory support, and transitioned to oral feeds while awaiting cardiac transplant.Twelve days later, he received a donor heart, with an uneventful recovery. He is now 3 years post‐transplant and has excellent graft function, and his transplant course has been unremarkable.Conclusion: Transcatheter‐based palliation for a neonate with critical AS, utilizing endoluminal PFRs, proved effective in stabilizing the infant and successfully bridging him to transplant. This highlights an opportunity for the utilization of PFRs in neonatal conditions where control of pulmonary blood flow is imperative as a bridge to transplantation.


  • Pediatric to Adult Transition in Solid Organ Transplant Recipients: A Systematic Review of Existing Transition Programs

    by Shivani Yerigeri, Matthew Satariano, Lars Pape, Jonathan N. Johnson, Stephen D. Marks, Katherine E. Twombley, Kush Doshi, Nikhil Harish, Jun Oh, Mignon McCulloch, et al.

    Background: Pediatric organ transplantation is the primary treatment for end‐organ failure. Improving medication adherence and healthcare compliance can decrease healthcare burdens, graft rejection, morbidity, and mortality. Adolescents commonly struggle with non‐adherence, necessitating a smooth transition to adult care. This systematic review aims to assess and evaluate the effectiveness of existing transition tools and models used in the care of pediatric solid organ transplant recipients (pSOTR).Methods: A systematic literature review of studies in electronic databases (PubMed, Google Scholar, and Mendeley) on interventions improving transition in pediatric solid organ transplant recipients (pSOTR) from 2000 to 2022 was conducted. Included studies involved pSOTR before the age of 12 years transitioning to adult care.Results: A lower proportion of graft acute rejection was observed among pSOTR with more than two transition interventions (10.088%, 95% CI: 0.901%–27.441%, I2 = 85.95%, p < 0.0001, random effects, five studies, n = 155) compared to those with two or fewer interventions (13.892%, 95% CI: 4.588%–27.142%, I2 = 74.73%, p = 0.0014, random effects, six studies, n = 140). Additionally, a significant association was found between transition protocols and lower rejection rates (χ2 = 10.57, p = 0.0011), with multiple protocols showing better outcomes (χ2 = 5.091, p = 0.024). Although adherence scores differed significantly with and without transition protocols (χ2 = 8.75, p = 0.0126), no significant difference was found between single and multiple protocol groups (χ2 = 4.8, p = 0.091).Conclusion: This review identifies various transition models and their impact on adherence and graft rejection, which correlate with morbidity and mortality and influence transplant outcomes. The heterogeneity of data within the current literature necessitates further research to establish causality and develop a standardized transition program aimed at improving patient outcomes.


  • Open Access

    Detection of Right and Left Ventricular Dysfunction in Pediatric Patients Using Artificial Intelligence–Enabled ECGs

    by Scott Anjewierden, Donnchadh O'SUllivan, Kathryn E. Mangold, Grace Greason, Itzhak Zachi Attia, Francisco Lopez‐Jimenez, Paul A. Friedman, Samuel J. Asirvatham, Jason Anderson, Benjamin W. Eidem, et al.

    Background: Early detection of left and right ventricular systolic dysfunction (LVSD and RVSD respectively) in children can lead to intervention to reduce morbidity and death. Existing artificial intelligence algorithms can identify LVSD and RVSD in adults using a 12‐lead ECG; however, its efficacy in children is uncertain. We aimed to develop novel artificial intelligence–enabled ECG algorithms for LVSD and RVSD detection in pediatric patients. Methods and Results: We identified 10 142 unique pediatric patients (age≤18) with a 10‐second, 12‐lead surface ECG within 14 days of a transthoracic echocardiogram, performed between 2002 and 2022. LVSD was defined quantitatively by left ventricular ejection fraction (LVEF). RVSD was defined semiquantitatively. Novel pediatric models for LVEF ≤35% and LVEF <50% achieved excellent test areas under the curve of 0.93 (95% CI, 0.89–0.98) and 0.88 (95% CI, 0.83–0.94) respectively. The model to detect LVEF <50% had a sensitivity of 0.85, specificity of 0.80, positive predictive value of 0.095, and negative predictive value of 0.995. In comparison, the previously validated adult data‐derived model for LVEF <35% achieved an area under the curve of 0.87 (95% CI, 0.84–0.90) for LVEF ≤35% in children. A novel pediatric model for any RVSD detection reached a test area under the curve of 0.90 (0.87–0.94). Conclusions: An artificial intelligence–enabled ECG demonstrates accurate detection of both LVSD and RVSD in pediatric patients. While adult‐trained models offer good performance, improvements are seen when training pediatric‐specific models.


  • Open Access

    “Acquired” sudden cardiac death high-risk genetic mutation in a heart transplant recipient

    by Luca Fazzini, Trista Brown, Matteo Castrichini, Alyssa K. Kroening, Marta Figueiral, Jonathan N. Johnson, Naveen L. Pereira


  • Top Cited Papers
    Open Access

    Addressing Disparities in Pediatric Congenital Heart Disease: A Call for Equitable Health Care

    by Devyani Chowdhury, Pietro A. Elliott, S. Yukiko Asaki, Shahnawaz Amdani, Quang‐Tuyen Nguyen, Christina Ronai, Seda Tierney, Victor Y. Levy, Kriti Puri, Carolyn A. Altman, et al.

    While significant progress has been made in reducing disparities within the US health care system, notable gaps remain. This article explores existing disparities within pediatric congenital heart disease care. Congenital heart disease, the most common birth defect and a leading cause of infant death, has garnered substantial attention, revealing certain disparities within the US health care system. Factors such as race, ethnicity, insurance coverage, socioeconomic status, and geographic location are all commonalities that significantly affect health disparities in pediatric congenital heart disease. This comprehensive review sheds light on disparities from diverse perspectives in pediatric care, demonstrates the inequities and inequalities leading to these disparities, presents effective solutions, and issues a call to action for providers, institutions, and the health care system. Recognizing and addressing these disparities is imperative for ensuring equitable care and enhancing the long‐term well‐being of children affected by congenital heart disease. Implementing robust, evidence‐based frameworks that promote responsible and safe interventions is fundamental to enduring change.